Lupin Pharmaceuticals, Inc.

Feb 01, 2021

Lupin Announces Partnership with Phil, Inc. in Support of SOLOSEC® (secnidazole)

Nov 16, 2020

Lupin Announces FDA Filing Acceptance of Supplemental New Drug Application for Solosec® (secnidazole) for the Treatment of Trichomoniasis

Aug 14, 2020

Lupin Presents Phase 3 Data for Solosec® (secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis

Jun 11, 2020

Lupin Pharmaceuticals and PlushCare Expand Access to Bacterial Vaginosis (BV) Treatment to Help Meet Patient Needs During COVID-19 Pandemic

Jun 09, 2020

Lupin Signs Marketing Agreement With Ceek for Women's Health Products to Improve OB/GYN and Patient Exam Experience

May 04, 2020

Lupin Announces Positive Topline Results From its Phase 3 Study of Single-Dose Solosec® (secnidazole) for the Treatment of Trichomoniasis

Apr 22, 2020

Lupin Announces SOLOSEC® (secnidazole) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.